Two 59%+ winners, four above 25% in Aug – How this AI model keeps picking winners
Beth Hecht, Chief Legal Officer and Corporate Secretary of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), a biopharmaceutical company with a market capitalization of approximately $904 million, recently sold 40,000 shares of the company’s common stock. The transaction, which took place on March 20, 2025, amounted to a total value of $217,244. The shares were sold at a weighted average price of $5.4311, with individual transaction prices ranging from $5.380 to $5.475. Following the sale, Hecht retains ownership of 1,353,510 shares directly. The stock, which has surged nearly 155% over the past year, is currently trading near its 52-week high of $5.54, with InvestingPro data indicating overbought conditions. Analysts maintain a strong buy consensus with a high price target of $8.Want deeper insights into insider trading patterns and comprehensive analysis? InvestingPro offers exclusive access to detailed insider transaction analysis and 10+ additional real-time trading signals for XERS.
In other recent news, Xeris Biopharma Holdings, Inc. reported its fourth-quarter 2024 earnings, exceeding expectations with an earnings per share of -0.03, compared to the forecasted -0.06. The company also surpassed revenue forecasts, reporting $60.1 million against the anticipated $55.99 million, marking a strong performance driven by products such as Recorlev and Gvoke. Additionally, Xeris has projected robust revenue growth for 2025, estimating between $255 million and $275 million, which is approximately a 30% increase. In another development, Xeris received FDA approval for its Gvoke VialDx™, a diagnostic aid for radiologic examinations, and announced a partnership with American Regent for its commercialization in the U.S. Moreover, H.C. Wainwright raised its price target for Xeris to $8.00 from $6.60, maintaining a Buy rating due to strong 2025 guidance and a path to cash flow breakeven. The firm’s analysis highlighted Xeris’s history of meeting or exceeding its guidance, further boosting investor confidence. These developments underscore Xeris’s strategic focus on expanding its product offerings and maintaining financial discipline.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.